October 9, 2025

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Announcement of the conclusion of Memorandum of Understanding (MOU) with the King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia

We are pleased to announce that we have concluded a Memorandum of Understanding (MOU) with the King Abdullah International Medical Research Center (KAIMRC) [1)], Saudi Arabia's largest medical research institution, to 1) develop the PAI-1 inhibitor RS5614 as a cancer treatment and anti-aging/longevity treatment, 2) participate jointly in the XPRIZE Healthspan[2)], and 3) advance collaboration toward commercialization in Saudi Arabia, etc.

1. Background and purpose of the Memorandum of Understanding (MOU)

Based on the anti-aging effects of the plasminogen activator inhibitor (PAI)-1 inhibitor RS5614, which we have been working on for many years, we have applied to the XPRIZE Healthspan in collaboration with domestic and international research institutions and medical institutions, including Tohoku University, Northwestern University, Tokai University, Hiroshima University, and Tokyo University of Science, with the concept of "a new small molecule drug (oral drug) that removes senescent cells and suppresses aging-related diseases without promoting carcinogenesis" (Senolytic drug[3),]) and were selected as one of the Top 40 semi-finalists in May 2025 and commenced the semi-final clinical trial in August 2025. Based on the results of this semi-final trial, the TOP10 finalists will be selected in the second half of 2026 (prize money of 1 million US dollars), and a four-year final clinical study will be conducted for the final competition.

Saudi Arabia is currently implementing an economic reform initiative called "Saudi Vision 2030[4)]," which aims to move away from oil dependency and diversify economic activities. A key goal of the Saudi Vision 2030 healthcare sector is to improve the productivity, quality, and efficiency of the healthcare system and thereby enhance the quality of life of its citizens. The King Abdullah International Medical Research Center (KAIMRC) is a core public research institute for biomedical and clinical research in Saudi Arabia, working in partnership with Saudi Arabian government agencies, such as the Ministry of Investment of Saudi Arabia (MISA) [5)], the Saudi Authority for Intellectual Property (SAIP) [6)], and the Saudi Food and Drug Authority (SFDA) [7)]. KAIMRC promotes seamless integration into the country's biotechnology ecosystem, supports commercialization, technology transfer, and long-term partnerships in line with the Saudi Vision

2030 initiative. KAIMRC is also part of the Saudi Arabian Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and is also a medical institution under the Ministry of National Guard-Health Affairs, which operates an extensive medical network throughout Saudi Arabia, including specialized hospitals, transplant centers, and primary and tertiary care facilities.

Our company and KAIMRC have signed the Memorandum of Understanding (MOU) for the purposes of clinical development and joint research of the PAI-1 inhibitor RS5614, as well as collaboration toward commercializing our pipeline in Saudi Arabia. Going forward, we hope to collaborate with the Saudi Arabian government and research/medical institutions, not only to contribute to Saudi Vision 2030, but also to accelerate the international expansion of our business.

2. Summary of the MOU

(1) Clinical development of PAI-1 inhibitor RS5614

Its clinical development in Saudi Arabia as a cancer treatment and anti-aging/longevity treatment

(2) Participation in the XPRIZE Healthspan collaborative research team

Participation in clinical trials at the XPRIZE Healthspan and conducting clinical trials in Saudi Arabia

(3) Development of programmed medical devices using artificial intelligence (AI)

Development of softwares as a medical device (SaMD) in Saudi Arabia that use artificial intelligence (AI) to support diabetes mellitus and maintenance hemodialysis that we are developing

(4) Business support for PAI-1 inhibitors and SaMD in Saudi Arabia

3. Signing Ceremony, etc.

In conjunction with the conclusion of this Memorandum of Understanding, a signing ceremony was held at the KSAU-HS Convention Center in Riyadh, Saudi Arabia, on October 1, 2025.

Photo of the signing ceremony



On the same day, Our Chairman and CEO, Toshio Miyata was invited to deliver several related presentations at the “Life Science Innovation Forum 2025,” hosted by the King Abdullah International Medical Research Center (KAIMRC) and co-hosted by the Ministry of Investment of Saudi Arabia (MISA) and J.P. Morgan Asset Management, held at the KSAU-HS Convention Center in Riyadh, Saudi Arabia.

Details of these presentations are featured in the news release dated October 2, 2025.

URL: https://www.renascience.co.jp/forum2025-2/

4. Future outlook

There is currently no impact on the financial results for the fiscal year ending March 2026, but we will promptly disclose any matters that need to be disclosed in the future.

[1] The King Abdullah International Medical Research Center (KAIMRC) is a leading institution for

biomedical and clinical research in Saudi Arabia. KAIMRK provides world-class infrastructure, scientific expertise, and strategic guidance to support innovators and biotech companies from around the globe as they enter the Saudi market. Through close collaboration with government stakeholders, KAIMRC facilitates seamless integration into the national biotechnology landscape. This approach promotes commercialization, knowledge transfer, and long-term partnerships aligned with Saudi Vision 2030.

[2] XPRIZE Healthspan
Sponsored by the Saudi Arabian Hevolution Foundation[9] and others, this is a competition organized by the XPRIZE Foundation with the goal of revolutionizing the treatment approach to human aging and longevity and actively extending healthy lifespan by 10 years or more. The competition will award a total of 100 million US dollars to research teams that can extend healthy lifespan by 2030.

[3]Senolytic drug
Senolytic drug is a drug that suppresses aging-related diseases without promoting carcinogenesis. The word is a combination of senescence and lytics.

[4] Saudi Vision 2030
Announced in 2016, this is a national strategy for Saudi Arabia, a national reform plan set forth by the Saudi Arabian government with the aim of breaking away from dependence on oil and diversifying the economy and society. It actively promotes international collaboration and investment in a variety of fields, including medicine, science and technology, tourism, and education.

[5] The Ministry of Investment of Saudi Arabia (MISA) is the Kingdom's lead agency for investment, cultivating a robust, business-friendly ecosystem and ensuring investors are supported at every step of their journey. Guided by Saudi Vision 2030, its mission is to promote Saudi Arabia as a world-class investment destination, attract and expand investments for sustainable economic growth, and help diversify the economy beyond oil. The ministry prioritizes high-impact sectors-such as a healthcare, biotechnology, and technology – to drive innovation and economic diversification, while forging international partnerships that position Saudi Arabia at the forefront of the global investment landscape

[6] The Saudi Arabian Authority for Intellectual Property (SAIP) is a Saudi Arabian government agency responsible for intellectual property rights, including patents, trademarks, and copyrights. It also participates in domestic and international intellectual property policies and international frameworks, contributing to the development of the knowledge economy.

[7] Saudi Food and Drug Authority (SFDA)
This is the government agency responsible for the approval and review of food and drug products

in Saudi Arabia. It is equivalent to the US Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

[8] J.P. Morgan Asset Management plays a crucial role in the biotechnology investment landscape by connecting emerging biotech ventures with global investors. As a strategic partner of this year’s forum, J.P. Morgan is dedicated to supporting the intersection of science and capital. The firm helps unlock opportunities for early-stage life science companies, facilitates access to growth capital, and promotes strategic partnerships to drive innovation across the global biotech industry.

[9]Hevolution Foundation
This was Launched in 2021 in Saudi Arabia and is a global non-profit organization that provides grants and early-stage investments to incentivize independent research and entrepreneurship in the emerging field of healthspan science. Vision: is to extend healthy lifespan for the benefit of all humanity. Mission: is to drive efforts to extend healthy human lifespan and understand the processes of aging, leveraging a broad set of tools through diverse approaches. In particular this foundation aims to:

- Increase the number of safe and effective treatments entering the market
- Compress the timeline of drug development, using the latest tools and technologies
- Increase accessibility to therapeutics that extend healthy lifespan